Effects of pemafibrate on CDAHFD-induced murine nonalcoholic steatohepatitis (NASH) model

Abstract

In this study, mice were fed with a choline-deficient methionine-reduced high-fat diet (CDAHFD) for 6 and 12 weeks to confirm the development of NASH pathology. We also evaluated the effects of pemafibrate, a selective PPARα modulator, on the progression of NASH pathology.

After 6 and 12 weeks, hepatic biomarkers for NASH, and hepatic mRNA expression for lipid accumulation, inflammation, and fibrosis increased over time, revealing the development of NASH pathology.

0.1 and 0.3 mg/kg of pemafibrate administered by gavage for 12 weeks completely prevented the progression of NASH pathology.